secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095417
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q2 net loss $9.2M; cash $69.7M; MDD collaboration with HMNC
------------------------------------------------------------------------------

- Net loss $9.2M for Q2 2024 vs $12.8M in Q2 2023; operating expenses down to $11.6M.
- Cash $69.7M as of June 30, 2024, expected to fund operations through end of 2025.
- Entered collaboration with HMNC to develop tildacerfont for major depressive disorder; HMNC funds Phase 2 study.
- Topline data from CAHmelia-204 and CAHptain-205 trials expected in Q4 2024.
- Collaboration revenue $1.6M from Kaken agreement, down from $2.2M in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/0000950170-24-095417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/sprb-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer